IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v32y2014i9p853-864.html
   My bibliography  Save this article

Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges

Author

Listed:
  • Kevin Marsh
  • Peng Xu
  • Panagiotis Orfanos
  • Agnes Benedict
  • Kamal Desai
  • Ingolf Griebsch

Abstract

Assessing the economic value of treatments for chronic myeloid leukaemia (CML) is important but poses a number of challenges. This paper reviews economic models of CML treatment to learn lessons from this experience and support ongoing efforts to model CML. A search of databases and submissions to key health technology assessment agencies identified 12 studies that reported 22 models. Common practice included the use of cohort Markov models—most models used health states organised around the key stages in CML: chronic phase, accelerated phase and blast phase—and the use of utility estimates in the literature that correspond with the National Institute for Health and Care Excellence reference case. Two key areas of uncertainty were the extrapolation of survival outcomes beyond the period observed by the trial; and the effectiveness of second-line therapies. Further work is required to overcome these uncertainties in existing models, such as longer-term trial data collection, including trials of second-line therapies; validation of health-related quality-of-life instruments; and the testing of alternative modelling approaches. In the meantime, it is important that the impact of uncertainties is tested through the use of sensitivity and scenario analysis. Copyright Springer International Publishing Switzerland 2014

Suggested Citation

  • Kevin Marsh & Peng Xu & Panagiotis Orfanos & Agnes Benedict & Kamal Desai & Ingolf Griebsch, 2014. "Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges," PharmacoEconomics, Springer, vol. 32(9), pages 853-864, September.
  • Handle: RePEc:spr:pharme:v:32:y:2014:i:9:p:853-864
    DOI: 10.1007/s40273-014-0177-3
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-014-0177-3
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.1007/s40273-014-0177-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Kevin Marsh & Peng Xu & Panagiotis Orfanos & James Gordon & Ingolf Griebsch, 2014. "Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Lymphocytic Leukaemia: A Review of Methods to Model Disease Outcomes and Estimate Utility," PharmacoEconomics, Springer, vol. 32(10), pages 981-993, October.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:32:y:2014:i:9:p:853-864. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.